Pacira Pharmaceuticals (NASDAQ:PCRX) : Investors lapped up stocks on upticks to the tune of $13.43 million in the Wednesdays trading session. The trading value on downticks was comparatively at $10.56 million and the uptick to downtick ratio of 1.27 indicates continuous buying by the bulls. The net money flow into the stock was $2.87 million. Upticks saw transactions worth $3.5 clearly indicating buying by large investors. The total money flow for block trades stood at $3.5 million, which is a positive for the stock in the long-term. Pacira Pharmaceuticals (NASDAQ:PCRX) fell $0.87 during the day at $38.01, a drop of -2.24% over the previous days close. However, for the week, the stock is -2.16%, compared to the previous week.
In an insider trading activity,The director of Pacira Pharmaceuticals, Inc., Brege Laura sold 1,000 shares at $46.95 on June 6, 2016. The Insider selling transaction had a total value worth of $46,950. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing. Currently the company Insiders own 6.9% of Pacira Pharmaceuticals shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -20.36% . During last six month period, the net percent change held by insiders has seen a change of -17.47%.
The company shares have dropped -44.46% from its 1 Year high price. On Dec 29, 2015, the shares registered one year high at $80.25 and the one year low was seen on Oct 7, 2015. The 50-Day Moving Average price is $43.48 and the 200 Day Moving Average price is recorded at $55.99. Pacira Pharmaceuticals (NASDAQ:PCRX): The stock opened at $39.02 on Wednesday but the bulls could not build on the opening and the stock topped out at $39.90 for the day. The stock traded down to $36.50 during the day, due to lack of any buying support eventually closed down at $38.01 with a loss of -2.24% for the day. The stock had closed at $38.88 on the previous day. The total traded volume was 1,227,878 shares.
Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, primarily for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control. DepoFoam is basis for the companys lead product candidate, EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other commercial product, DepoCyt(e), which the Company manufactures for its commercial partners, as well as its other product candidates. The Companys other product candidates include DepoMeloxicam and DepoTranexamic Acid.